WEBULL
WebtradeDownload

Can Certara (CERT) Justify Its Valuation On Stronger Q3 Results And Tighter 2026 Guidance?

Simply Wall St · 1d ago

Certara (CERT) just put fresh numbers on the table, reporting third quarter 2026 results with higher sales and net income versus a year earlier, along with tighter full year revenue growth guidance of 2% to 3%.

The share price reaction has been brisk rather than euphoric. Certara is now trading at US$11.90 after a 30 day share price return of 27.14% and a 90 day gain of 48.75%. The 1 year total shareholder return of 42.86% contrasts with a weaker 3 and 5 year record, which hints that momentum has recently improved as investors reassess both growth potential and risk around the business following the updated 2026 guidance.

Scan how Certara compares with other healthcare software players, which are showing tight guidance and recent share price momentum, by reviewing our curated list of 35 healthcare AI stocks.

Bulls point to Certara’s earnings rebound and tighter guidance, while bears focus on the multi year losses and long term share price record. Which side does the current valuation actually support?

Most Popular Narrative: 7% Overvalued

Certara last closed at $11.90, while the analyst consensus Narrative on Simply Wall St puts fair value at $11.08. This implies the stock trades modestly above that estimate using an 8.36% discount rate and higher margin forecasts.

The upcoming commercial launch of Certara's next-generation, AI-enabled MIDD platform and CertaraIQ QSP software leverages advanced analytics and machine learning, providing differentiated capabilities that democratize access and increase the potential customer base, which should translate to higher recurring revenue and margin expansion through cloud-based SaaS models.

Integration of newly acquired businesses (like Applied BioMath and Formedix), combined with more robust cross-selling between consulting and software offerings, positions Certara to drive higher deal sizes and improve operating leverage, which strengthens both net margins and operating income over time.

See why 9 investors see Certara as 7% overvalued.

Result: Fair Value of $11.08 (OVERVALUED)

Still, the narrative can unravel if pharma customers slow adoption of Certara’s software, or if rising R&D and integration costs keep profitability under pressure.

Find out about the key risks to this Certara narrative.

Next Steps

If the tone of this Certara update feels mixed, consider this a cue to move quickly and review the upside drivers yourself via the 1 key reward.

Looking for more investment ideas beyond Certara?

If Certara has sharpened your focus on quality, do not stop here. The best opportunities rarely wait around for investors who move slowly.